The rat monoclonal antibody M17/4 reacts with an extracellular epitope of CD11a (alpha-subunit of murine LFA-1), a 180 kDa type I transmembrane glycoprotein expressed on B and T lymphocytes, monocytes, macrophages, neutrophils, basophils and eosinophils.
Cross-Reactivity (Details)
Mouse
Purification
Purified by protein-G affinity chromatography.
Purity
> 95 % (by SDS-PAGE)
Immunogen
C57BL/6 mouse splenic secondary cytotoxic T lymphocytes
Beyer, Wang, Peters, Doths, Koerner-Rettberg, Openshaw, Schwarze: "The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo." in: Respiratory research, Vol. 6, pp. 70, (2005) (PubMed).
Koseki, Miura, Fujimori, Hokari, Komoto, Hara, Ogino, Nagata, Goto, Hachimura, Kaminogawa, Ishii: "In situ demonstration of intraepithelial lymphocyte adhesion to villus microvessels of the small intestine." in: International immunology, Vol. 13, Issue 9, pp. 1165-74, (2001) (PubMed).
Papayannopoulou, Priestley, Nakamoto, Zafiropoulos, Scott, Harlan: "Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice." in: Blood, Vol. 97, Issue 5, pp. 1282-8, (2001) (PubMed).
Sanchez-Madrid, Davignon, Martz, Springer: "Antigens involved in mouse cytolytic T-lymphocyte (CTL)-mediated killing: functional screening and topographic relationship." in: Cellular immunology, Vol. 73, Issue 1, pp. 1-11, (1983) (PubMed).
Integrin subunit alpha L,CD11a (LFA-1 alpha) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity.,LFA-1, LFA1A, ITGAL